Suven Life Sciences has been granted a product patent each by China and Eurasia corresponding to a new chemical entity (NCE) for the treatment of disorders associated with neurodegenerative diseases.
According to a BSE filing, these patents are valid till 2034.
“We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical needs with a huge market potential globally,” Suven Life CEO Venkat Jasti said.
The granted claims of the patents are being developed as therapeutic agents useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson’s and schizophrenia, the filing added.
Suven Life Sciences shares were trading down 6.29 per cent at Rs 272.50 on the BSE.
